BrainStorm Cell Therapeutics Provides Update on FDA Advisory Committee Meeting to Review NurOwn for the Treatment of ALS

BrainStorm Cell Therapeutics Inc. announced the outcome of the U.S. Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee meeting to review the Biologics License Application for NurOwn®, an investigational mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis.